As a result of the current Federal government funding situation, the information on this website may not be up to date or acted upon.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit

Updates regarding government operating status and resumption of normal operations can be found at

New platform developed to link clinical data with electronic health records

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
  • Posted: February 21, 2012
NCI Press Office


To make data gathered from patients in clinical trials available for use in standard care, the National Cancer Institute (NCI) has created a new computer tool to support interoperability between clinical research and electronic health record systems. This new software represents an innovative solution for rapid and accurate data exchange between systems with diverse applications and information models, a task that is normally time and resource-intensive. 

The platform leverages templates developed by the healthcare industry’s standards making body, known as Health Level 7, or HL7.  The templates use what is known as Clinical Document Architecture (CDA). The systems that receive the data will be able to parse and use it to facilitate secondary analyses – another step towards precision medicine. The software, which will be freely available under an open-source license, will be in use later this year as part of NCI’s unique platform known as TRANSCEND.  This platform will support clinical trials beginning with a breast cancer trial known as I SPY2, led by Laura Esserman, M.D., at the University of California San Francisco. Through the adoption of this software, healthcare providers will be able to make progress in fulfilling some of the mandated criteria for the meaningful use of electronic health records, and clinical trial sites will be able to improve efficiency and quality.  This can speed the delivery of new therapies as well as furnish physicians with the details of a patient’s study participation.